1. Home
  2. CMRC vs SLN Comparison

CMRC vs SLN Comparison

Compare CMRC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commerce.com Inc.

CMRC

Commerce.com Inc.

HOLD

Current Price

$2.80

Market Cap

224.4M

Sector

N/A

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.31

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMRC
SLN
Founded
2009
1994
Country
United States
United Kingdom
Employees
1079
116
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.4M
236.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CMRC
SLN
Price
$2.80
$6.31
Analyst Decision
Buy
Buy
Analyst Count
4
5
Target Price
$4.88
$42.60
AVG Volume (30 Days)
815.6K
262.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.11
N/A
Revenue Next Year
$4.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$4.19
52 Week High
$5.55
$8.40

Technical Indicators

Market Signals
Indicator
CMRC
SLN
Relative Strength Index (RSI) 47.22 41.75
Support Level $2.56 $5.91
Resistance Level $3.13 $7.21
Average True Range (ATR) 0.26 0.53
MACD -0.04 -0.17
Stochastic Oscillator 10.39 14.29

Price Performance

Historical Comparison
CMRC
SLN

About CMRC Commerce.com Inc.

Commerce.com Inc is engaged in offering a Software-as-a-Service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which the majority of its revenue is generated from Americas-U.S.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: